Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolododekin alfa - Ankyra Therapeutics

Next Previous
Drug Profile

Tolododekin alfa - Ankyra Therapeutics

Alternative Names: ANK-101

Latest Information Update: 06 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ankyra Therapeutics
  • Class Antineoplastics; Cytokines; Drug conjugates; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Interleukin 12 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 06 Aug 2025 Ankyra Therapeutics plans a phase I trial in Squamous cell cancer (In adolescents, In adults, In the elderly, Metastatic disease, Second-line therapy or greater) (Intratumoural) (NCT07100925)
  • 18 Jun 2025 Ankyra Therapeutics plans a phase I trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metatstatic disease) (Intratumoural), in August 2025 (NCT07027514)
  • 29 Apr 2025 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Solid tumours released by Ankyra Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top